At least six native and non-native PD-1 inhibitors, including camrelizumab, sintilimab, toripalimab, tislelizumab, nivolumab and pembrolizumab are available for HCC patients in China (7, 20–22). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.